Serum Institute CEO Adar Poonawalla plans to begin vaccine production outside India
The pharma giant, which manufactures the AstraZeneca COVID-19 vaccine is going to make a formal announcement in the next few days
BusinessToday.In | May 1, 2021 | Updated 09:29 IST
Adar Poonawalla, Chief Executive Officer (CEO) of the Serum Institute of India poses for a picture at the Serum Institute of India, Pune. (Photo: Reuters)
Pune-based Serum Institute of India (SII) is planning to begin vaccine production outside India as it struggles to meet supply commitments. The pharma giant, which manufactures the AstraZeneca COVID-19 vaccine is going to make a formal announcement in the next few days.
Updated:
May 01, 2021 17:47 IST
The State had placed a demand for 50 lakh vaccine doses in advance to launch the vaccination campaign for 1.57 crore population in the 18-44 age-bracket
Share Article
AAA
Jharkhand CM Hemant Soren flashes the victory sign as he receives a dose of COVID-19 vaccine in Ranchi, Thursday, April 29, 2021.
| Photo Credit:
PTI
The State had placed a demand for 50 lakh vaccine doses in advance to launch the vaccination campaign for 1.57 crore population in the 18-44 age-bracket Facing delay in vaccine supplies, Jharkhand which could not launch the inoculation drive for the people in the age-group of 18-44 years on Saturday, has sought Centre s intervention for facilitating procurement of at least 50 lakh vaccine doses, Chief Minister Hemant Soren said.
Jharkhand fails to launch 3rd phase of vaccination drive for want of supply of additional vaccine stock
SECTIONS
Jharkhand fails to launch 3rd phase of vaccination drive for want of supply of additional vaccine stockPTI
Last Updated: May 01, 2021, 05:02 PM IST
Share
Synopsis
The state had placed demand for 50 lakh vaccine doses in advance to launch the vaccination campaign for 1.57 crore population in the 18-44 age-bracket under the Liberalised and Accelerated Phase 3 Strategy of COVID-19 vaccination for which registration had commenced since April 28.
Agencies There are issues concerning supplies and we have written to the central government for facilitating procurement of at least 50 lakh doses, Soren told .
Sri Lanka is looking at sources other than India to purchase the Oxford/AstraZeneca vaccine in view of delay in securing the vaccines from the Serum Institute of India, health authorities said on Saturday. The supply is being delayed from India. We have to understand that India has to look after their own country before supplying to us. It is not that they have told no to us, Gen Shavendra Silva, the chief of the COVID prevention operations told reporters. Silva said that presidential advisor Lalith Weeratunga was looking at other country sources to buy the coronavirus vaccines. Sri Lanka was left with only 300,000 jabs of India-manufactured Covishield when it started rolling out the second jab.
Sri Lanka looking at sources outside India to purchase AstraZeneca vaccine due to supply delay
SECTIONS
Last Updated: May 01, 2021, 02:42 PM IST
Share
Synopsis The supply is being delayed from India. We have to understand that India has to look after their own country before supplying to us. It is not that they have told no to us, Gen Shavendra Silva, the chief of the COVID prevention operations told reporters.
Reuters
3,709,189.0
Sri Lanka is looking at sources other than India to purchase the Oxford/AstraZeneca vaccine in view of delay in securing the vaccines from the Serum Institute of India, health authorities said on Saturday. The supply is being delayed from India. We have to understand that India has to look after their own country before supplying to us. It is not that they have told no to us, Gen Shavendra Silva, the chief of the COVID prevention operations told reporters.